Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 1/20 | 0.56 |
| ▸ | FNTB | P49356 | 1/20 | 0.56 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.56 |
| ▸ | LTA4H | P09960 | 1/20 | 0.55 |
| ▸ | NPY1R | P25929 | 1/20 | 0.54 |
| ▸ | NPY2R | P49146 | 1/20 | 0.54 |
| ▸ | NPY4R | P50391 | 1/20 | 0.54 |
| ▸ | MME | P08473 | 1/20 | 0.54 |
| ▸ | BACE1 | P56817 | 2/20 | 0.53 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3646826 | 1.00 | FNTA (0.56) | FNTAFNTBPGGT1BLTA4HNPY1R | |
| SCHEMBL907359 | 1.00 | FNTA (0.56) | FNTAFNTBPGGT1BLTA4HNPY1R | |
| Acetic Acid SCHEMBL15201182 | 0.98 | LTA4H (0.56) | FNTAFNTBPGGT1BLTA4HNPY1R | |
| Acetic Acid SCHEMBL15201179 | 0.98 | LTA4H (0.56) | FNTAFNTBPGGT1BLTA4HNPY1R | |
| Formic Acid SCHEMBL27865482 | 0.96 | FNTA (0.52) | FNTAFNTBPGGT1BLTA4HNPY1R | |
| SCHEMBL16430978 | 0.96 | LTA4H (0.58) | FNTAFNTBPGGT1BLTA4HMME | |
| SCHEMBL16430977 | 0.96 | LTA4H (0.58) | FNTAFNTBPGGT1BLTA4HMME | |
| SCHEMBL30917374 | 0.94 | FNTA (0.56) | FNTAFNTBPGGT1BLTA4HBACE1 | |
| SCHEMBL16556113 | 0.92 | NPY4R (0.56) | FNTAFNTBPGGT1BNPY1RNPY2R | |
| SCHEMBL16556111 | 0.92 | NPY4R (0.56) | FNTAFNTBPGGT1BNPY1RNPY2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 174 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3497445-A2 | MICROPATTERNING ASSEMBLY, METHODS FOR MICROPATTERNING, AND MICROPATTERNED DEVICES | Institute of Science and Technology Austria (AT) | 2019-06-19 | — | — | EP | claimed |
| WO-2018029315-A2 | MICROPATTERNING ASSEMBLY, METHODS FOR MICROPATTERNING, AND MICROPATTERNED DEVICES | IST AUSTRIA - INSTITUTE OF SCIENCE AND TECHNOLOGY AUSTRIA (AT) | 2018-02-15 | — | — | WO | claimed |
| EP-1800692-B1 | Immunological compositions and vaccines containing N-formyl methionyl peptide as adjuvant | CONNAUGHT TECHNOLOGY CORP (US) | 2011-01-26 | — | — | EP | claimed |
| EP-2198298-A1 | ALLERGY TEST BASED ON FLOW CYTOMETRIC ANALYSIS | Bühlmann Laboratories AG (CH) | 2010-06-23 | — | — | EP | claimed |
| WO-2009033691-A1 | ALLERGY TEST BASED ON FLOW CYTOMETRIC ANALYSIS | BÜHLMANN LABORATORIES AG (CH) | 2009-03-19 | — | — | WO | claimed |
| EP-1599226-A4 | A METHOD OF DIAGNOSIS AND TREATMENT | MEDVET SCIENCE PTY LTD (AU) | 2007-11-21 | — | — | EP | claimed |
| EP-1800692-A1 | Novel adjuvant for subunit or component vaccines | Connaught Technology Corporation (US) | 2007-06-27 | — | — | EP | claimed |
| EP-1599226-A1 | A METHOD OF DIAGNOSIS AND TREATMENT | MEDVET SCIENCE PTY. LTD. (AU) | 2005-11-30 | — | — | EP | claimed |
| WO-2004073739-A1 | A METHOD OF DIAGNOSIS AND TREATMENT | MEDVET SCIENCE PTY. LTD. (AU) | 2004-09-02 | — | — | WO | claimed |
| US-12622975-B2 | Peptide-conjugated prodrugs | BRANDEIS UNIVERSITY (US) | 2026-05-12 | — | — | US | disclosed |
| US-20250289907-A1 | PHOSPHATIDYLSERINE TARGETING MOLECULE COMBINED WITH MEMORY T CELL ANTIGEN FOR THERAPEUTIC, DIAGNOSTIC AND ADJUVANT USE | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2025-09-18 | — | — | US | disclosed |
| CN-119757441-A | Efficient and stable solid nuclear magnetic resonance heteronuclear correlation spectrum method | 武汉科技大学 | 2025-04-04 | — | — | CN | disclosed |
| CN-113631703-B | Using poloxacin viral conduction of amines | 瑞威帝基因传递股份有限公司 | 2025-03-25 | — | — | CN | disclosed |
| US-20240366627-A1 | SMALL MOLECULES FOR MOUSE SATELLITE CELL PROLIFERATION | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2024-11-07 | — | — | US | disclosed |
| US-5043424-A | Modification method for peptides and proteins by reacting with a phosphoric acid ester | KAO CORPORATION (JP) | 1991-08-27 | — | — | US | disclosed |
| EP-0438497-A1 | VASOPERMEABILITY-ENHANCING CONJUGATES. | UNIV SOUTHERN CALIFORNIA (US) | 1991-07-31 | — | — | EP | disclosed |
| EP-0398143-A1 | Labeled chemotactic peptides to image focal sites of infection or inflammation | THE GENERAL HOSPITAL CORPORATION (US) | 1990-11-22 | — | — | EP | disclosed |
| WO-1990013317-A1 | LABELED CHEMOTATIC PEPTIDES TO IMAGE FOCAL SITES OF INFECTION OR INFLAMMATION | THE GENERAL HOSPITAL CORPORATION (US) | 1990-11-15 | — | — | WO | disclosed |
| WO-1990003801-A1 | VASOPERMEABILITY-ENHANCING CONJUGATES | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 1990-04-19 | — | — | WO | disclosed |
| EP-0312963-A2 | Modification method for peptides and proteins | Kao Corporation (JP) | 1989-04-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12622975-B2 | Peptide-conjugated prodrugs | PEPD, PAM, VIP | FNTA 734/4885FNTB 479/4885PGGT1B 1338/4885 |
| US-20240366627-A1 | SMALL MOLECULES FOR MOUSE SATELLITE CELL PROLIFERATION | MKI67, MYLK2, MYH2 | FNTA 3918/4885FNTB 2810/4885PGGT1B 2205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.